Innovent Biologics, Inc. (HKEX: 01801), a China-based biopharmaceutical company, announced on Thursday that it has partnered with WeComput, a Chinese company that says it integrates artificial intelligence, biophysics, and high-performance computing technologies to create a unique digital, intelligent and automated platform for drug molecule generation, design and simulation.

The partnership is aimed at jointly advancing the construction and improvement of Innovent Biologics' Artificial Intelligence for Drug Discovery platform. Through this collaboration, both parties will combine their respective strengths and technologies to further accelerate the drug discovery and development process using AI technology.

Within the partnership, Innovent Academy will utilise WeComput's WeMol, a molecular design platform, to build and enhance its computing infrastructure, accelerating the drug research and development process. Meanwhile, WeMol will integrate NVIDIA's BioNeMo to further expand the computing capability of Innovent's AI systems and improve computational efficiency.

Both parties say that they will integrate their technological strengths to create a comprehensive AI-driven drug discovery and development system that is efficient, user-friendly, digitalised, intelligent and automated. This cooperation is intended to allow Innovent to significantly reduce AI implementation and experimental costs, shorten the drug R&D cycle, improve R&D success rate, and deliver more innovative drugs and treatment options to patients.